AC
CDLX icon

Allstate Corporation’s Cardlytics CDLX Stock Holding History

Allstate Corporation’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-420
Closed -$278K – 614
2021
Q4 		$278K Sell
420
-10
-2% -$7.64K 0.01% 728
2021
Q3 		$361K Sell
430
-1
-0.2% -$1.01K 0.01% 580
2021
Q2 		$547K Buy
431
+1
+0.2% +$1.13K 0.02% 499
2021
Q1 		$471K Sell
430
-31
-7% -$40.9K 0.01% 554
2020
Q4 		$658K Sell
461
-53
-10% -$56.5K 0.02% 392
2020
Q3 		$363K Buy
514
+65
+14% +$47.3K 0.01% 522
2020
Q2 		$314K Buy
+449
New +$259K 0.01% 571

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
JCM
JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return

Allstate Corporation's CDLX Position: Q1 2022 in Review

Allstate Corporation sold out of Cardlytics (CDLX) in Q1 2022, closing a stake of 420 shares — an estimated $278K sold.

Allstate Corporation first reported a position in CDLX in Q2 2020 and held it in 7 quarters. The position peaked at $658K in Q4 2020. 153 funds tracked by Wall St. Rank hold CDLX as of Q1 2022.

  • Allstate Corporation reported no remaining Cardlytics position as of Q1 2022 after selling out during the quarter.
  • Allstate Corporation sold 420 Cardlytics shares in Q1 2022, an estimated $278K.
  • Allstate Corporation first reported a position in Cardlytics in Q2 2020 and held it in 7 quarters.
  • Allstate Corporation's Cardlytics position peaked at $658K in Q4 2020.
  • 153 funds tracked by Wall St. Rank held Cardlytics as of Q1 2022.

Based on Allstate Corporation's 13F filing for Q1 2022, filed 16 May 2022.